CIS

Home page

CIS

Mass vaccination with CoviVac to be launched in spring

20 February 2021 14:09 (UTC +04:00)

Mass inoculation against COVID-19 with the CoviVac vaccine developed by the Chumakov Federal Scientific Center for the Research and Development of Immune and Biological Products is scheduled to begin in spring, Russian Science and Higher Education Minister Valery Falkov said on Saturday, APA reports citing TASS.

"Today, two domestic vaccines are used extensively and are proving their efficacy. The registration of the third vaccine will solidify our position as a country with strong scientific and technological capabilities," the Ministry of Science and Higher Education quotes him as saying.

According to Falkov, the third phase of CoviVac trials is scheduled for March, 3,000 people will take part in it.

The minister noted that "in 2020, when the world was confronted with the coronavirus pandemic, society reconsidered its views of the importance of scientific activities, the importance of scientists’ work." He stressed that "Russian science once again proved its superiority by creating the world’s first coronavirus vaccine."

The Chumakov Federal Scientific Center for the Research and Development of Immune and Biological Products is a subordinate institution of the Russian Science and Higher Education Ministry. The CoviVac vaccine is recommended for individuals aged between 18 and 60.